According to a post on the FDA’s website, Denali Therapeutics’ treatment of Mucopolysaccharidosis type IIIA received orphan designation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DNLI:
- Denali Therapeutics price target lowered to $27 from $32 at Citi
- Denali Therapeutics’ ALS Drug Fails Phase 2, Yet MS Trial Continues
- Denali announces data, expansion of BBB-crossing enzyme replacement therapy
- Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
- Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™